Loading clinical trials...
Loading clinical trials...
This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
M.D. Anderson Cancer Center
NCT06144671 · Solid Tumor, Adult
NCT07539441 · Central Nervous System Tumors, Glioma
NCT06132828 · Solid Tumor
NCT04570423 · Solid Tumors, Lymphoma
NCT03581318 · Normal and Abnormal Cardiovascular Physiology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions